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ORIGINAL SCIENTIFIC PAPER
Determinants of changes in pulmonary artery pressure in patients with
severe aortic stenosis treated by transcatheter aortic valve implantation
Mihai Strachinaru, Ben Ren, Bas M. van Dalen, Nicolas Van Mieghem, Peter P. T. De Jaegere, Lennart van
Gils, Tjebbe W. Galema and Marcel L. Geleijnse
Department of Cardiology, Thorax Center, Erasmus MC, Rotterdam, The Netherlands
ABSTRACT
Background: Elevated pulmonary artery pressure (PAP) in patients with severe aortic stenosis (AS)
is a strong predictor of adverse prognosis. This study sought to assess the relation between PAP
and clinical and echocardiographic parameters in elderly patients with severe AS, as well as to
identify the determinants of the change in PAP after transcatheter aortic valve implantation (TAVI).
Methods: The study included 170 subjects (age 81± 7 years, 45% men) with symptomatic
severe AS who were treated by TAVI. They underwent a clinical evaluation and a transthoracic
echocardiography before the TAVI procedure and 6 months after.
Results: In a multivariable analysis, the independent predictors for baseline PAP were the body
mass index (BMI) (b¼ 0.21, p¼ .006), COPD GOLD class (b¼ 0.20; p¼ .009), the E/e0 ratio
(b¼ 0.20; p¼ .02) and the degree of aortic regurgitation (b¼ 0.20; p¼ .01). After TAVI, there was
significantly less (51% vs. 29%, p<.0001) pulmonary hypertension, defined as a tricuspid regurgi-
tation velocity 2.8 m/s. The baseline variables related to an improvement in PAP were the tri-
cuspid regurgitation velocity (p¼ .0001) and the E/e0 (p¼ .005). From the parameters potentially
modified with TAVI, the only independent predictor of PAP variation was the change in the E/e0
ratio (b¼ 0.23; p¼ .01).
Conclusions: Independent predictors for baseline PAP in elderly patients with symptomatic AS
were the BMI, GOLD class, the aortic regurgitation and the E/e0 ratio. The baseline predictors for
a change in PAP 6 months after TAVI were the baseline PAP and E/e0, with only the change in
the E/e0 ratio being correlated to the change in PAP.
ARTICLE HISTORY
Received 10 October 2019
Revised 5 December 2019
Accepted 19 December 2019
KEYWORDS
Pulmonary artery pressure;
TAVI; E/e0 ratio; diastolic
dysfunction
Introduction
Aortic stenosis (AS) is the most common valvular heart
disease in the Western world and its prevalence is
expected to increase due to the aging of the popula-
tion [1]. The rise in pulmonary artery pressure (PAP) in
these patients has been clearly demonstrated as a
strong predictor of worse prognosis after medical, sur-
gical or interventional management [2–4]. We also
know from several studies that PAP improves after
relieving the valvular obstacle [5–7]. There is however
little data concerning the determinants of this rise in
PAP and in particular on the factors associated with
post interventional improvement in PAP [8–12]. This
study sought to assess the relation between PAP and
clinical and echocardiographic parameters in patients
with severe AS, as well as to identify the determinants
of improvement in PAP after transcatheter aortic valve
implantation (TAVI).
Methods
The study design was monocentric and retrospective,
involving patients treated by TAVI for severe AS
between 2005 and 2014 in our institution. The study
was conducted according to the principles of the
Declaration of Helsinki. Retrospective clinical studies
are waived for approval by our Institutional Ethical
Committee. All patients have given written consent for
the use of their anonymised data in this research.
Patient population
After exclusion of patients with prior aortic or mitral
valvular surgery, mitral stenosis or significant areas of
focal LV akinesia (defined as an akinetic region extend-
ing to at least three segments, involving the basal
septum and/or the basal lateral wall), the study
included 170 subjects (mean age 81± 78 years, 45%
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men) with symptomatic severe AS, defined as an aor-
tic valve area less than 1 cm2 and/or less than 0.6 cm2/
m2 and/or a mean pressure gradient over 40mmHg,
who were treated by TAVI. All patients underwent a
clinical evaluation and a transthoracic echocardiog-
raphy at baseline before the TAVI procedure and at
6 months post-TAVI.
Venous blood samples were drawn from each
patient within 30min of the Doppler echocardiog-
raphy study after 30min of supine rest. For NT-proBNP
determination, an electrochemiluminescence immuno-
assay (ProBNP Elecsys, Roche Diagnostics GmbH,
Mannheim, Germany) was used. Due to the very large
range of values of the natriuretic peptide and the
abnormal distribution of this variable, the log10 of the
NT proBNP was used in the analysis.
Transthoracic echocardiography
Two-dimensional echocardiography was performed
using a Philips iE33 system (Philips, Best, The
Netherlands) with the patient in the left lateral decubi-
tus position. Echocardiographic studies were per-
formed by an independent experienced
echocardiographer, blinded to the patient’s clinical
status. All echocardiograms were saved as video loops
or still frames in a digital database and were reana-
lysed by an experienced cardiologist (MS). LV ejection
fraction was calculated using the biplane modified
Simpson rule. The mitral inflow velocity profile (E/A
wave ratio, E wave deceleration time) was assessed
with pulsed-wave Doppler. The early diastolic veloc-
ities at the septal annulus level were assessed with
pulse-wave tissue Doppler from a standard apical four-
chamber view [13]. Pulmonary artery pressure was
estimated from the trans-tricuspid systolic gradient.
Tricuspid annular systolic excursion (TAPSE) was meas-
ured in standard apical four-chamber view.
Each echocardiographic measurement was per-
formed by at least two different observers: one initial
by the sonographer performing the study, validated
by a supervising imaging cardiologist; and a second
measurement performed by MS (highly experienced
imaging cardiologist), who was blinded to the clinical
status of the subjects during these measurements. In
case of disagreement between the two observers, a
highly experienced imaging cardiologist (MG) acted as
third observer and adjusted the result.
Definitions
Obesity was defined as a body mass index (BMI)
above 30 kg/m2 [14]. COPD was classified according to
GOLD class [15]. Severe impairment of the renal func-
tion was defined as GFR less than 30ml/min/1.73 m2,
present for more than 3 months, as estimated by the
2009 CKD-EPI creatinine equation [16]. Aortic and
mitral regurgitations were assessed semiquantitatively
according to current guidelines for the evaluation of
native valves [17]. Pulmonary hypertension (PHT) was
considered at a value of the trans-tricuspid systolic
gradient above 2.8 m/s [18]. Significant coronary artery
disease was defined as >50% stenosis in at least one
coronary artery.
Statistical analysis
Continuous variables are presented as means (±SD) if
normally distributed. Categorical variables are pre-
sented as frequencies and percentages. Differences
between continuous variables were assessed by the
paired-samples t test and between categorical varia-
bles by chi-square test. Univariate linear regression
was used to identify the factors related to PAP level.
The factors found to be significant in univariate ana-
lysis or considered relevant based on clinical data
were entered into a multivariable linear regression
model. The overall performance of the regression
model was assessed using R2 statistics. Collinearity
diagnostics and Durbin–Watson’s statistics were used
to check the assumptions of no multicollinearity and





Male gender 76 (45%)
BMI > 30 kg/m2 31 (18%)
Diabetes 40 (24%)
Hypertension 91 (54%)
Severe renal dysfunction 19 (11%)
Atrial fibrillation 34 (20%)
Pacemaker before TAVI 15 (9%)
LBBB before TAVI 29 (17%)
Coronary artery disease 92 (54%)
Previous CABG 38 (22%)
Previous PCI 38 (22%)
PCI along with TAVI 19 (11%)
COPD GOLD 2-4 49 (29%)
Pulmonary hypertension 86 (51%)
NYHA class I 10 (6%)
NYHA class II 53 (31%)
NYHA class III-IV 102 (60%)
Log10 NT-proBNP 2.3 ± 0.6
Angina 47 (27%)
Syncope 15 (9%)
BMI: body mass index; CABG: coronary artery by-pass graft surgery;
COPD: chronic obstructive pulmonary disease; GOLD: Global Initiative for
Chronic Obstructive Lung Disease classification of COPD; LBBB: left bundle
branch block; NYHA class: New York Heart Association classification of
heart failure symptoms; PCI: percutaneous coronary intervention; NT-
proBNP: N-terminal pro brain natriuretic peptide.
Data are presented as mean ± SD or number (percentage %).
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serial independence of errors. A two-sided p value less
than .05 was used for declaring statistical significance.
All statistical analyses were performed with SPSS 21.0
software (SPSS Inc, Chicago, IL).
Results
The baseline characteristics of the population are
shown in Table 1. All patients were symptomatic. Ten
patients (6%) were in NYHA class I, 53 patients (31%)
were in NYHA class II and 102 patients (60%) were in
NYHA class III or IV (in five patients NYHA class could
not be determined due to immobility). Forty-six
patients (27%) had angina and 15 (9%) syncope.
Significant COPD (class 2–4) was present in 49 patients
(29%), obesity in 32 (18%), severe renal dysfunction in
19 (11%). Ninety-two of these patients (54%) had cor-
onary artery disease, in 38 (22%) already treated by
coronary bypass surgery and in 38 (22%) by a percu-
taneous intervention. In addition, a percutaneous
intervention was performed along with the TAVI inter-
vention in 19 (11%) patients. PHT was present in 86
patients (51%). A pacemaker was already present
before the TAVI procedure in 15 (9%) and a complete
left bundle branch block (LBBB) was diagnosed at
baseline in 29 (17%).
Determinants of PHT at baseline
In univariate analysis, COPD class, mitral and aortic
insufficiency, ejection fraction and E/e0 ratio (Table 2,
Figure 1) were related to baseline PAP. In a multivari-
able analysis, the independent predictors for PHT were
BMI (Beta ¼ 0.21; p¼ .006), COPD GOLD class (Beta ¼
0.20; p¼ .009), aortic regurgitation (Beta ¼ 0.20;
p¼ .01) and the E/e0 ratio (Beta ¼ 0.20; p¼ .02).
Baseline predictors of improvement in pulmonary
artery pressure
Before TAVI, 86 patients (51%) had PHT (Table 3). After
TAVI an improvement in PAP, defined as a decrease in
trans-tricuspid systolic gradient as compared to the
baseline value, was noted in 101 patients (59%). No
improvement or increased gradient was noted in 69
(41%). After TAVI, the number of PHT patients was sig-
nificantly lower (50; p<.0001) and 36 (21%) PHT
patients normalised the PAP.
When comparing the baseline parameters in the
group with improved trans-tricuspid gradient versus
the group without improvement, the only significantly
different variables are the baseline value of the trans-
tricuspid gradient and the E/e0 ratio (Figure 2).
Variation of clinical and echographic parameters
6 months after TAVI
There was a significant decrease in NYHA class, mean
transaortic gradient, as well as in tricuspid regurgita-
tion velocity (Table 4). We noted a significant decrease
in Log10NT-proBNP from 2.3 ± 0.6 at baseline to
2.1 ± 0.5 six months after TAVI (p¼ .002). There was no
significant change in the mean degree of mitral and
aortic regurgitation. The E and A wave velocity
increased significantly, without improvement of mean
ejection fraction or E/e0 ratio.
A new-onset (not present at baseline) LBBB was
noticed in 67 (39%) patients. Implantation of a new
Table 2. Baseline determinants of PHT.
N¼ 170 Univariate analysis Multivariable analysis
Parameter Mean ± SD Beta p Beta p
Age 81 ± 7 –0.14 .08
Male gender –0.08 .28
BMI 26 ± 5 0.09 .26 0.21 .006
COPD GOLD class (0–4) 0.78 ± 0.99 0.19 .01 0.20 .009
Mitral regurgitation (0–3) 1.09 ± 0.65 0.15 .05 0.10 .21
Aortic regurgitation (0–3) 0.91 ± 0.69 0.23 .003 0.20 .01
Mean transaortic gradient (mmHg) 44 ± 15 0.09 .23 0.11 .20
Ejection fraction (%) 55 ± 12 –0.21 .006 –0.15 .10
E/e0 septal 21 ± 9 0.28 <.0001 0.20 .02
TAPSE baseline (mm) 20 ± 5 –0.067 .39
Atrial fibrillation 0.12 .11
LBBB at baseline 0.10 .19
Pacemaker at baseline 0.01 .86
Coronary artery disease –0.03 .66
Sever renal failure –0.13 .11
Diabetes 0.06 .42
Hypertension –0.02 .77
BMI: body mass index; CI: confidence intervals; COPD: chronic obstructive pulmonary disease; LBBB: left bundle branch block; TAPSE: tri-
cuspid annular plane systolic excursion; SD: standard deviation.
Data are presented as mean ± SD. Significant p values (<.05) are highlighted in bold.
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pacemaker (not present at baseline) was indicated in
46 patients (27%).
Right ventricular function parameters in the whole
group did not change significantly (baseline TAPSE ¼
20.03 ± 5.4mm; six months after TAVI the average
TAPSE ¼ 20.12 ± 5.2mm; p¼ .73).
Parameter variation as determinants of a change
in PAP 6 months after TAVI
In univariate and multivariate analyses, only the
change in E/e0 ratio was a predictor of a change in
PAP (Table 5, Figure 3).
Discussion
The main findings of this study in patients with severe
AS treated with TAVI were: (1) the independent deter-
minants of the baseline value of the PAP were BMI,
the GOLD classification of COPD, aortic regurgitation
and E/e0 ratio, (2) there was a significant improvement
in PAP 6 months after TAVI, with significantly less
patients having PHT, (3) the baseline parameters pre-
dicting an improvement in PAP were the tricuspid
regurgitation velocity and the E/e0 ratio, and (4) the
change in E/e0 ratio was the only predictor of a
change in PAP.
PHT is noted in 28–56% of the patients with AS,
depending on the definition threshold [3,4,7,9] and
clinical characteristics. Elderly persons with severe AS
undergoing TAVI may have several comorbidities,
especially COPD, leading to a significant increase in
PAP that is relatively unrelated to AS. They may also
have concomitant regurgitant lesions of the left heart
valves that contribute to an increase in PAP. In our
study, PHT was present in 51% of patients. Several fac-
tors were shown to be related to a rise in PAP in uni-
variate analysis: the GOLD classification of COPD,
Figure 1. Correlation plot between baseline values of the E/e0 ratio and the value of the pulmonary artery pressure as derived
from the maximal transtricuspid gradient. A correlation line was fitted to the data (central thick line), as well as 95% confidence
intervals (thin lateral lines).
Table 3. Comparison between no improvement or worsening






Age 80 ± 8 82 ± 6 .06
Male gender 34 (49%) 42 (42%) .32
BMI > 30 kg/m2 12 (17%) 20 (20%) .15
Diabetes 16 (23%) 24 (24%) .9
Hypertension 37 (54%) 54 (54%) .98
Severe renal dysfunction 9 (13%) 10 (10%) .52
Atrial fibrillation 16 (23%) 18 (18%) .39
Coronary artery disease 36 (52%) 56 (55%) .67
PCI along with TAVI 5 (7%) 14 (14%) .17
COPD GOLD 2–4 19 (28%) 30 (30%) .76
NYHA class I 3 (4%) 7 (7%) .48
NYHA class II 27 (39%) 26 (26%) .06
NYHA class III–IV 37 (54%) 65 (64%) .16
LVEDP 19 ± 7 19 ± 7 1
COPD GOLD class (0–4) 0.71 ± 1 0.82 ± 1 .48
Mitral regurgitation (0–3) 1.1 ± 0.6 1.1 ± 0.7 1
Aortic regurgitation (0–3) 0.9 ± 0.7 0.92 ± 0.7 .85
Mean transaortic gradient (mmHg) 42 ± 15 46 ± 15 .09
Ejection fraction (%) 55 ± 12 55 ± 13 1
E/e0 septal 22 ± 10 18 ± 7 .005
Tricuspid regurgitation Vmax 2.6 ± 0.4 2.9 ± 0.5 .0001
TAPSE baseline (mm) 19.7 ± 5 20.3 ± 5 .44
LBBB before TAVI 13 (19%) 16 (16%) .61
Pacemaker present 6 (9%) 9 (9%) .44
Log BNP 2.4 ± 0.5 2.3 ± 0.6 .24
LVEDP: left ventricular end-diastolic pressure.
Data are presented as mean ± SD. Significant p values (<.05) are high-
lighted in bold.
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mitral or aortic regurgitation, E/e0 ratio, and ejection
fraction. Surprisingly, the trans-aortic gradient did not
reach statistical significance. Moreover, the multivari-
able model including these parameters yielded only
Figure 2. Comparison between the groups of patients who improved their transtricuspid gradient 6 months after TAVI implant-
ation (left boxplots) and the ones who did not improve or increased their gradient (right boxplots). The only significantly different
parameters measured at baseline (before TAVI) according to our analysis were the E/e0 ratio (A) and maximal velocity of the tricus-
pid regurgitation (B). The higher E/e0 ratio and higher transtricuspid gradient probably reflect a more advanced state of disease in
the patients who did not show improvement in pulmonary artery pressure after TAVI.
Table 4. Variation of clinical and echocardiographic variables after TAVI.
N¼ 170
Variable Mean variation ± SD
95% confidence interval
pLower Upper
NYHA class (I–IV) –0.9 ± 0.8 –1.05 –0.81 <.0001
Tricuspid regurgitation peak velocity –0.1 ± 0.4 –0.04 –0.16 .001
Mean transaortic gradient (mmHg) –35 ± 16 –38 –33 <.0001
Mitral regurgitation (0–3) –0.05 ± 0.6 –0.14 0.05 .326
Aortic regurgitation (0–3) –0.09 ± 0.9 –0.24 0.05 .198
Ejection fraction (%) –0.03 ± 9 –1.38 1.32 .966
E wave amplitude (cm/s) 5 ± 26 1.2 9.21 .01
A wave amplitude (cm/s) 13 ± 27 8.32 18.03 <.0001
E/A ratio –0.09 ± 0.55 –0.19 0.003 .058
E wave deceleration time (ms) 12 ± 99 –4 28 .147
Septal e0 (cm/s) 0.24 ± 1.6 –0.01 0.50 .065
E/e0 ratio –0.18 ± 7.3 –1.03 1.38 .770
TAPSE (mm) –0.09 ± 3 –0.59 0.42 .733
Log10 NT-proBNP 0.13 ± 0.5 0.05 0.20 .002
Data are presented as mean ± SD. Significant p values (<.05) are highlighted in bold.
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four independent predictors for PHT: COPD severity,
filling pressures of the left ventricle, reflected by the
E/e0 ratio, BMI and aortic insufficiency. This is in con-
cordance with data already present in the literature,
showing that diastolic function of the left ventricle is
the main predictor of elevated PAP in severe AS [12].
The role of COPD severity is obvious, especially in this
elderly population in whom chronic pulmonary dis-
ease is not rare. The fact that BMI was not significant
in the univariate analysis, but very significant in the
multivariate cannot be explained by our statistical
model, but the result is consistent with previous find-
ings [19]. It could be due to the influence of the BMI
on the prevalence of hypertension, diabetes and cor-
onary artery disease (factors that were not entered in
the multivariable analysis due to their lack of impact
in the univariate model). Numerous publications
address the prognostic role of the postprocedural
paravalvular leak [20], but there is very little recent
data on the impact of pre-procedural native valve aor-
tic insufficiency associated to AS [21].
In our study, there was an overall statistically sig-
nificant improvement in PAP, but only 59% really
improved, and only 21% normalised the PAP. The
value of the PAP was unchanged or even worsened in
41%. This may explain the little overall variation of the
mean PAP. There was also a significant improvement
in transaortic gradient without significant changes in
the ejection fraction and the overall degree of mitral
and aortic insufficiency. The effect of TAVI on the ejec-
tion fraction has indeed been reported as either neu-
tral or positive [22–24]. In a recent meta-analysis, a
non-significant trend towards a reduction in mitral
regurgitation was reported [25], consistent with our
findings. The change in aortic regurgitation is of
course, very variable, depending on the baseline
Table 5. Parameter variation as determinants of pulmonary artery pressure change 6 months after TAVI.
N¼ 170 Univariate analysis Multivariable analysis
D parameter Mean variation ± SD Beta p Beta p
D mean transaortic gradient (mmHg) –35 ± 16 –0.11 .16 –0.07 .45
PCI with TAVI 0.09 .25 0.02 .86
D mitral regurgitation (0–3) –0.10 ± 0.58 0.09 .22 –0.11 .21
D aortic regurgitation (0–3) –0.12 ± 0.94 0.12 .13 0.17 .07
D ejection fraction (%) 0.09 ± 8.55 –0.13 .11 –0.01 .96
D E/e0 ratio –0.04 ± 7.36 0.27 .001 0.23 .01
D TAPSE (mm) –0.1 ± 3 0.09 .19 0.01 .84
New onset LBBB after TAVI 0.06 .44 0.06 .55
New pacemaker implantation 0.09 .24 0.12 .21
CI: confidence intervals; PCI: percutaneous coronary intervention; SD: standard deviation.
Data are presented as mean ± SD. Significant p values (<.05) are highlighted in bold.
Figure 3. Correlation plot between the variation of the E/e0 ratio before and after the TAVI procedure (delta E/e0) and the vari-
ation of the pulmonary artery pressure (delta PAP) as derived from the maximal transtricuspid gradient. A correlation line was fit-
ted to the data (central thick line), as well as 95% confidence intervals (thin lateral lines).
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characteristics of each patient as well as numerous
technical factors [26].
It has already been noted that PAP improves after
successful TAVI intervention (according to VARC 2 cri-
teria [20]). This is most likely due to the removal of
the valvular obstacle and the possible improvement in
left ventricular systolic and diastolic function or valvu-
lar regurgitation. The persistence of PHT is considered
to impact long-term prognosis in patients with severe
AS [11]. The improvement in PAP was related to the
initial value of the PAP and the E/e0 ratio. Very few
studies investigated this particular matter, and only in
the setting of surgical valvular replacement, but the
results are similar [5,27]. Higher values of PAP and E/e0
may suggest a more advanced disease in which the
beneficial effects after TAVI may be less important.
The only independent dynamic variable predicting a
change in PAP after TAVI proved to be the change in
the E/e0 ratio.
The general clinical improvement, demonstrated by
a significant decrease of the NYHA class, was reflected
in echocardiography by a decrease in tricuspid regur-
gitation peak velocity and mean transaortic gradient
(Table 4). This improvement was correlated with a
similar evolution of the biomarkers of elevated intra-
cardiac pressure, as observed in heart failure in gen-
eral [28] and in elderly patients with AS [13].
After TAVI, the mitral inflow E and A waves had sig-
nificantly higher amplitudes, but the E/e0 ratio did not
change considerably. The E/e0 ratio has a paradoxical
evolution: although it was a significant determinant of
the baseline PAP and of the improvement in PAP, its
mean value did not change significantly. There could
be several explanations to the paradoxical behaviour
of this parameter, that does not change in spite of the
significant change in PAP. One explanation may reside
in an early and sustained increase in cardiac output
after relieving the aortic obstacle (as reflected by the
rise in E and A velocities through an unchanged mitral
valve). Also, improvement of the septal e0 velocity
could be limited in the presence of a prosthetic valve
very close to the mitral septal point. However, the role
of the diastolic function as measured by the E/e0 ratio
is reinforced by the fact that the other main potential
factors influencing the PAP (left heart valvular regurgi-
tation, LV ejection fraction, severity of the pulmonary
disease and right ventricular function) did not show
any significant correlations in this study.
The debate on the optimal site of e0 measurement
is still going on but the septal site seems to correlate
best to direct and indirect measurements of LV filling
pressures [13,29,30].
A new-onset LBBB or the implantation of a new
pacemaker did not demonstrate a significant effect on
the PAP in our patients, in univariate and multivari-
ate analysis.
Clinical implications
PAP evaluation by echocardiography needs to be a
part of the prognostic estimation of potential TAVI
candidates [20, 31], along with the filling pressures of
the left ventricle, the two elements being intercon-
nected. COPD and obesity remain clinical features to
be considered when estimating the role of AS in the
rise of PAP. The improvement in the filling pressures
of the left ventricle after relieving the valvular obs-
tacle, although insignificant on the population level,
seems to be the main factor contributing to the
reduction in PAP.
Study limitations
This is a retrospective cross-sectional study, but the
quality of the data was not compromised because
data acquisition has been done according to a very
strict prospectively defined TAVI protocol. The limited
number of patients is also a potential problem in
interpreting statistical models, especially when the
number of variables is important. However, the level
of statistical significance was sufficient to sustain our
conclusions. The evaluation of PAP by echocardiog-
raphy has several known limitations [32,33] but was
preferred due to its lack of risk for the patient, as
compared to invasive measurements. Finally, in AS
patients, the evaluation of the aortic regurgitation is
already difficult [17]. Estimating its change can be
even more so, since it is a comparison of valvular
regurgitation with a paraprosthetic leak.
Conclusions
Independent predictors for baseline PAP in elderly
patients with symptomatic AS were the BMI, GOLD
class and left ventricular filling pressure reflected by
the E/e0 ratio. The baseline variables related to a
change in PAP 6 months after TAVI were the baseline
PAP and E/e0, with only the change in the E/e0 ratio
being correlated to the change in PAP.
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